| Name | Title | Contact Details |
|---|
Meridian Heights Afc is a Sault Sainte Marie, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Many well-being programs give you tools to manage your health. We go deeper. WellSpark is a leading health and well-being company that administers one of the largest value-based well-being programs in the country. Our well-being portal is certified for information security by the Health Information Trust (HITRUST) Alliance, and our health risk assessment earned the Wellness and Health Promotion certification form the National Committee for Quality Assurance (NCQA). WellSpark delivers a full-suite of well-being products and solutions for businesses, municipalities, and consumers. Participants benefit from robust education to improve health literacy, promote early detection of diseases and provide condition management through coaching, care coordination, social services and more. By understanding any socio-economic and behavioral barriers preventing proper self-care, WellSpark programs can uniquely empower individuals to embrace healthier lifestyles. Lives improve when well-being solutions spark results. Go beyond basic health and well-being with WellSpark Health.
We are a developer, manufacturer and marketer of prefabricated, semi-custom and custom orthoses. Orthomerica is known for providing exceptional customer service, quality, innovation and prompt delivery of orthopaedic braces to the orthotics and
Illinois Bone and Joint Institute is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Illinois Bone and Joint Institute is based in Morton Grove, IL. You can find more information on Illinois Bone and Joint Institute at www.ibji.com
Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona’s lead program is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. Clinical trials for Sanfilippo types A and B are anticipated to begin in 2015.